Indoleamine 2,3 Dioxygenase 1 Market
Indoleamine 2,3 Dioxygenase 1 Market Size, Share, and Trends Analysis Report by Type (BMS-986205, Dcellvax, Epacadostat, F-001287, Galanal, and Others), and by Application (Alopecia, Cervical Cancer, Gastric Cancer, Glioma, and Others) Forecast Period (2026-2035)
Industry Overview
Global indoleamine 2,3 dioxygenase 1 market was valued at $420.1 million in 2025 and is projected to reach $832.2 million by 2035, growing at a CAGR of 7.1% from 2026 to 2035. The global market is witnessing steady development driven by sustained research activity and increasing strategic interest in novel therapeutic mechanisms. Growing awareness of complex disease biology has encouraged the exploration of targeted approaches that address underlying immune and metabolic pathways. Pharmaceutical developers are aligning resources toward differentiated product pipelines with long-term clinical relevance. This focus is supported by improvements in drug discovery platforms and translational science capabilities. Additionally, favorable research funding environments in key regions continue to support early- and mid-stage development. Collectively, these factors contribute to a measured yet consistent progression of the global market.
Market Dynamics
Rising Focus on Immunometabolism Pathways
The global market is expanding as research increasingly concentrates on immunometabolic mechanisms that regulate immune tolerance and disease progression. Growing scientific validation of enzyme-driven immune modulation has encouraged deeper investment in targeted therapeutic development. Pharmaceutical companies are prioritizing precision approaches to address complex conditions where conventional therapies show limited efficacy. This shift is supported by advances in translational research that improve target identification and patient stratification. Enhanced collaboration between academic institutions and industry players has further accelerated innovation. As a result, the market continues to gain momentum through a more refined and evidence-driven development landscape.
Expansion of Oncology and Specialty Indications
Market growth is also driven by the broadening scope of applications across oncology and select specialty disorders with high unmet clinical needs. The increasing incidence of complex cancers has prompted sustained demand for novel therapeutic options that can be integrated into combination treatment strategies. Regulatory frameworks in key regions are evolving to support accelerated development pathways for innovative therapies. At the same time, improved clinical trial designs are generating more robust efficacy and safety data. These factors collectively strengthen investor confidence and long-term development commitments. Consequently, the market demonstrates steady progress supported by application-led expansion rather than volume-based growth.
Market Segmentation
- Based on the type, the market is segmented into bms-986205, Dcellvax, Epacadostat, f-001287, Galanal, and others.
- Based on the Application, the market is segmented into Alopecia, Cervical Cancer, Gastric Cancer, Glioma, and Others.
Epacadostat Segment to Lead the Market with the Largest Share
Epacadostat represents the leading sub-segment within the type-based classification due to its advanced clinical development history and extensive evaluation across multiple therapeutic indications. It has attracted sustained attention from pharmaceutical developers because of its well-characterized mechanism of action and its potential compatibility with combination therapies. The compound has generated substantial clinical and scientific data, providing a stronger evidence base compared to other candidates in the segment. This depth of research has positioned it as a reference molecule for ongoing and future development efforts. Continued analysis of trial outcomes has also informed next-generation program designs. As a result, this sub-segment maintains prominence in shaping overall market direction.
Cervical Cancer: A Key Segment in Market Growth
Cervical cancer emerges as the leading application sub-segment, driven by the persistent unmet need for effective therapeutic options in advanced and recurrent cases. The disease burden remains significant across both developed and emerging regions, supporting sustained research focus and investment. Targeted therapeutic approaches are being explored to improve treatment response and durability beyond conventional standards of care. Clinical interest is further reinforced by the potential for integration with existing treatment regimens. Ongoing studies continue to refine patient selection and therapeutic positioning. These factors collectively establish cervical cancer as a key driver within the application landscape.
Regional Outlook
The global indoleamine 2,3 dioxygenase 1 market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region Dominates the Market with a Major Share
North America represents a leading region due to its strong concentration of research-driven pharmaceutical companies and advanced clinical development infrastructure. The region benefits from well-established regulatory frameworks that support innovative drug development and early adoption of novel therapeutic approaches. High levels of research funding and a mature clinical trial ecosystem contribute to sustained progress in this market. Collaboration between biotechnology firms, academic institutions, and healthcare providers further strengthens development pipelines. In addition, the presence of specialized oncology centers facilitates advanced clinical evaluation. These factors collectively position North America as a primary contributor to regional market activity.
Asia-Pacific Region to Contribute to the Market Growth
Asia-Pacific emerges as another key region, supported by expanding pharmaceutical manufacturing capabilities and increasing investment in biomedical research. Countries within the region are strengthening their clinical research networks and regulatory environments to attract global development programs. Rising healthcare expenditure and growing awareness of advanced therapeutic options contribute to regional momentum. Local companies are increasingly engaging in innovative research through partnerships and in-house development initiatives. The large and diverse patient population also supports efficient clinical trial execution. As a result, the Asia-Pacific continues to gain strategic importance within the global market landscape.
Market Players Outlook
The major companies operating in the global indoleamine 2,3 dioxygenase 1 market include Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, and Incyte Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In 2017, Bristol-Myers Squibb publicly announced encouraging responses in a Phase 1/2a study combining its investigational IDO1 inhibitor BMS-986205 with Opdivo (nivolumab) in heavily pre-treated advanced cancer patients, showing immunomodulation and tumor responses in early clinical cohorts.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global indoleamine 2,3 dioxygenase 1 market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Indoleamine 2,3 Dioxygenase 1 Market Sales Analysis – Type | Application ($ Million)
- Indoleamine 2,3 Dioxygenase 1 Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Indoleamine 2,3 Dioxygenase 1 Industry Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Indoleamine 2,3 Dioxygenase 1 Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Indoleamine 2,3 Dioxygenase 1 Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Indoleamine 2,3 Dioxygenase 1 Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Indoleamine 2,3 Dioxygenase 1 Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Indoleamine 2,3 Dioxygenase 1 Market Revenue and Share by Manufacturers
- Indoleamine 2,3 Dioxygenase 1 Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Bristol-Myers Squibb Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- li Lilly and Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Incyte Corp.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck & Co., Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Bristol-Myers Squibb Company
- Key Company Analysis
- Global Indoleamine 2,3 Dioxygenase 1 Market Sales Analysis by Type ($ Million)
- BMS-986205
- Dcellvax
- Epacadostat
- F-001287
- Galanal
- Others
- Global Indoleamine 2,3 Dioxygenase 1 Market Sales Analysis by Application ($ Million)
- Alopecia
- Cervical Cancer
- Gastric Cancer
- Glioma
- Others
- Regional Analysis
- North American Indoleamine 2,3 Dioxygenase 1 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Indoleamine 2,3 Dioxygenase 1 Market Sales Analysis – Type | Application | JKL | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Indoleamine 2,3 Dioxygenase 1 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Others)
- Rest of Asia-Pacific
- Rest of the World Indoleamine 2,3 Dioxygenase 1 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Antido Therapeutics (Australia) Pty Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BirchBioMed Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol-Myers Squibb Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CanBas Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Company
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Emcure Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hoffmann-La Roche Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Gerologix Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Incyte Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- IO Biotech ApS
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Jiangsu Hengrui Medicine Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Kyowa Hakko Kirin Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Kyowa Kirin Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lumos Pharma, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Luye Pharma Group Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Nammi Therapeutics Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- NewLink Genetics Corp.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Orpheris Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Secarna Pharmaceuticals GmbH & Co. KG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shanghai De Novo Pharmatech Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Syntekabio Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Antido Therapeutics (Australia) Pty Ltd.
1. Global Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Type, 2025-2035 ($ Million)
2. Global BMS-986205 Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Region, 2025-2035 ($ Million)
3. Global Dcellvax Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Region, 2025-2035 ($ Million)
4. Global Epacadostat Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Region, 2025-2035 ($ Million)
5. Global F-001287 Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Region, 2025-2035 ($ Million)
6. Global Galanal Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Region, 2025-2035 ($ Million)
7. Global Others Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Region, 2025-2035 ($ Million)
8. Global Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Application, 2025-2035 ($ Million)
9. Global Indoleamine 2,3 Dioxygenase 1 For Alopecia Market Research And Analysis By Region, 2025-2035 ($ Million)
10. Global Indoleamine 2,3 Dioxygenase 1 For Cervical Cancer Market Research And Analysis By Region, 2025-2035 ($ Million)
11. Global Indoleamine 2,3 Dioxygenase 1 For Gastric Cancer Market Research And Analysis By Region, 2025-2035 ($ Million)
12. Global Indoleamine 2,3 Dioxygenase 1 For Glioma Market Research And Analysis By Region, 2025-2035 ($ Million)
13. Global Indoleamine 2,3 Dioxygenase 1 For Others Market Research And Analysis By Region, 2025-2035 ($ Million)
14. Global Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Geography, 2025-2035 ($ Million)
15. North American Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Country, 2025-2035 ($ Million)
16. North American Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Type, 2025-2035 ($ Million)
17. North American Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Application, 2025-2035 ($ Million)
18. European Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Country, 2025-2035 ($ Million)
19. European Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Type, 2025-2035 ($ Million)
20. European Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Application, 2025-2035 ($ Million)
21. Asia-Pacific Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Country, 2025-2035 ($ Million)
22. Asia-Pacific Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Type, 2025-2035 ($ Million)
23. Asia-Pacific Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Application, 2025-2035 ($ Million)
24. Rest Of The World Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Country, 2025-2035 ($ Million)
25. Rest Of The World Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Type, 2025-2035 ($ Million)
26. Rest Of The World Indoleamine 2,3 Dioxygenase 1 Market Research And Analysis By Application, 2025-2035 ($ Million)
1. Global Indoleamine 2,3 Dioxygenase 1 Market Share By Type, 2025 Vs 2035 (%)
2. Global BMS-986205 Indoleamine 2,3 Dioxygenase 1 Market Share By Region, 2025 Vs 2035 (%)
3. Global Dcellvax Indoleamine 2,3 Dioxygenase 1 Market Share By Region, 2025 Vs 2035 (%)
4. Global Epacadostat Indoleamine 2,3 Dioxygenase 1 Market Share By Region, 2025 Vs 2035 (%)
5. Global F-001287 Indoleamine 2,3 Dioxygenase 1 Market Share By Region, 2025 Vs 2035 (%)
6. Global Galanal Indoleamine 2,3 Dioxygenase 1 Market Share By Region, 2025 Vs 2035 (%)
7. Global Others Indoleamine 2,3 Dioxygenase 1 Market Share By Region, 2025 Vs 2035 (%)
8. Global Indoleamine 2,3 Dioxygenase 1 Market Share By Application, 2025 Vs 2035 (%)
9. Global Indoleamine 2,3 Dioxygenase 1 For Alopecia Market Share By Region, 2025 Vs 2035 (%)
10. Global Indoleamine 2,3 Dioxygenase 1 For Cervical Cancer Market Share By Region, 2025 Vs 2035 (%)
11. Global Indoleamine 2,3 Dioxygenase 1 For Gastric Cancer Market Share By Region, 2025 Vs 2035 (%)
12. Global Indoleamine 2,3 Dioxygenase 1 For Glioma Market Share By Region, 2025 Vs 2035 (%)
13. Global Indoleamine 2,3 Dioxygenase 1 For Others Market Share By Region, 2025 Vs 2035 (%)
14. Global Indoleamine 2,3 Dioxygenase 1 Market Share By Region, 2025 Vs 2035 (%)
15. US Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
16. Canada Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
17. UK Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
18. France Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
19. Germany Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
20. Italy Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
21. Spain Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
22. Russia Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
23. Rest Of Europe Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
24. India Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
25. China Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
26. Japan Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
27. South Korea Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
28. ASEAN Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
29. Australia and New Zealand Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
30. Rest Of Asia-Pacific Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
31. Latin America Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
32. Middle East And Africa Indoleamine 2,3 Dioxygenase 1 Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Indoleamine 2,3 Dioxygenase 1 Market in 2025 is estimated to be around $420.1 million.
North America holds the largest share in the Indoleamine 2,3 Dioxygenase 1 Market.
Leading players in the Indoleamine 2,3 Dioxygenase 1 Market include Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, and Incyte Corp., among others.
The Indoleamine 2,3 Dioxygenase 1 Market is expected to grow at a CAGR of 7.1% from 2026 to 2035.
The Indoleamine 2,3 Dioxygenase 1 Market growth is driven by increasing cancer research and growing development of novel immunotherapy treatments targeting IDO1 pathways.
